What medications are recommended for patients with diabetes and heart failure?

Medication Recommendations for Patients with Diabetes and Heart Failure

For patients with diabetes and heart failure, sodium-glucose cotransporter 2 (SGLT2) inhibitors are the first-line medication recommendation due to their proven benefits in reducing heart failure hospitalizations, cardiovascular death, and improving symptoms and quality of life.

First-Line Therapy Recommendations

For Type 2 Diabetes with Heart Failure:

1. SGLT2 inhibitors

   • First-line therapy for patients with heart failure (both reduced and preserved ejection fraction) 1
   • Demonstrated significant reduction in:
     • Heart failure hospitalizations
     • Cardiovascular death
     • Improvement in symptoms and quality of life 1
   • Examples: empagliflozin, canagliflozin, dapagliflozin 1
   • Empagliflozin specifically showed 35% reduction in heart failure hospitalization in the EMPA-REG OUTCOME trial 2

2. Metformin

   • May be continued in patients with stable heart failure if eGFR remains >30 mL/min/1.73 m² 1
   • Should be avoided in unstable or hospitalized heart failure patients 1
   • Generally considered safe in stable heart failure patients 1, 3

Second-Line/Additional Therapy:

1. GLP-1 receptor agonists

   • Recommended for patients with established atherosclerotic cardiovascular disease 1
   • Examples: liraglutide, semaglutide, dulaglutide 1
   • Consider adding to SGLT2 inhibitor for additive cardiovascular benefit 1

2. ACE inhibitors or ARBs

   • Recommended for patients with heart failure, particularly with reduced ejection fraction 1
   • Reduce risk of cardiovascular events 1

3. Beta-blockers

   • Indicated for heart failure with reduced ejection fraction 1
   • Should be continued for at least 3 years after myocardial infarction 1

Medications to Avoid

1. Thiazolidinediones (pioglitazone, rosiglitazone)

   • Strongly contraindicated in heart failure patients 1
   • Associated with increased risk of heart failure 1

2. DPP-4 inhibitor saxagliptin

   • Associated with increased risk of heart failure hospitalization 1
   • Should be avoided in patients with heart failure 1

Special Considerations

• Heart Failure with Reduced Ejection Fraction (HFrEF):

  • SGLT2 inhibitors are first-line therapy 1
  • Add beta-blockers with proven cardiovascular benefit 1
  • Consider ACE inhibitors/ARBs 1

• Heart Failure with Preserved Ejection Fraction (HFpEF):

  • SGLT2 inhibitors are recommended 1
  • Diuretics for symptom management if fluid overload present 1

• Renal Function Monitoring:

  • Regular monitoring of renal function required with SGLT2 inhibitors and ACE inhibitors/ARBs
  • Adjust metformin dose based on eGFR 1

Treatment Algorithm

1. Initial Assessment:

   • Determine heart failure type (HFrEF vs. HFpEF)
   • Assess renal function (eGFR)
   • Evaluate cardiovascular risk factors

2. First-Line Treatment:

   • Start SGLT2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin) 1
   • If patient is already on metformin and stable with adequate renal function, continue metformin 1

3. Additional Therapy Based on Specific Needs:

   • For HFrEF: Add beta-blockers and ACE inhibitors/ARBs 1
   • For atherosclerotic disease: Consider adding GLP-1 receptor agonist 1
   • For fluid overload: Add diuretics 1

4. Monitoring:

   • Regular assessment of renal function
   • Heart failure symptoms
   • Glycemic control
   • Cardiovascular outcomes

Clinical Pearls and Pitfalls

• Common Pitfall: Continuing thiazolidinediones in heart failure patients - these should be discontinued due to increased heart failure risk 1

• Important Consideration: While metformin was historically contraindicated in heart failure, current evidence supports its use in stable heart failure patients with adequate renal function 1, 3

• Caution: Saxagliptin has been associated with increased risk of heart failure hospitalization and should be avoided 1

• Optimization Strategy: Consider combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist for additive cardiovascular benefits in high-risk patients 1